Gastrohepatic Disorders

Biologic Therapies Compared in Patients With Moderate-to-Severe Crohn's Disease

By June 20, 2018

For this study, researchers identified randomized controlled trials that included adults with moderate-to-severe CD treated with various biologic agents (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab) as first- or second-line therapies compared with placebo or an active comparator.

Pharmacologic Tx Should Be Used Sparingly for Reflux in Preemies

June 19, 2018

There is a lack of evidence for efficacy of pharmacologic agents and emerging evidence of significant harm; consequently, these agents should be used sparingly, if at all.

A4250 Granted Rare Pediatric Disease Designation for Progressive Cholestasis

By June 13, 2018

The first patient has been enrolled in PEDFIC-1, a phase 3, single, randomized, double-blind, placebo-controlled trial designed to evaluate A4250 in 60 patients (aged 6 months-18 years) with PFIC subtype 1 or 2 who have elevated serum bile acid (sBA) levels and pruritus.

Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis

June 13, 2018

The researchers found that 31% of the patients assigned to bezafibrate had a complete biochemical response (normal levels of total bilirubin, alkaline phosphatase, aminotransferases, and albumin as well as a normal prothrombin index) vs none assigned to placebo.

Honey + Sucralfate May Reduce Injury After Accidental Button Battery Ingestion

By June 11, 2018

Noting that infants and children who ingest button batteries can experience esophageal damage leading to significant morbidity and death in as little as 2 hours, researchers from the Children's Hospital of Philadelphia and Nationwide Children's Hospital aimed to identify effective options for mitigating these effects by testing common weakly acidic household beverages, viscous liquids, and sucralfate (Carafate).

DDW: Psych Disorders Make GERD Hard to Dx by Symptoms Alone

June 06, 2018

The researchers found that the mean DeMeester score was 44 ± 33 for GERD+ and 7 ± 4 for GERD−. For GERD+ and GERD−, the mean HADS scores for anxiety (8 for both; P=0.2) and depression (5 and 6, respectively; P=.3) did not differ significantly.

Stelara Linked to Reduced Rates of Hospitalization, Surgery in Crohn's Disease

By June 04, 2018

The new analysis pooled patients from the UNITI-1 and UNITI-2 trials who had clinical response after a single intravenous (IV) dose of ustekinumab and entered a 5-year follow-up period.

FDA Approves New Treatment Option for Ulcerative Colitis

By May 30, 2018

The expanded FDA approval was based on results from two 8-week placebo-controlled induction trials and a 52-week maintenance study.

Consensus Guidelines for the Prevention of Postoperative Nausea and Vomiting

May 30, 2018

The latest Consensus Guidelines for the Management of PONV (CGM-PONV) recommend an assessment of a patient's baseline risk for PONV using a validated risk score based on independent predictors.

HCV Guidelines Updated to Include Recommendations for Key Populations

By May 25, 2018

The guidelines were developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.

Ingestible Device Could Monitor Gastrointestinal Health

May 25, 2018

"IMBEDs enable new opportunities for gastrointestinal biomarker discovery and could transform the management and diagnosis of gastrointestinal disease," the authors write.

Review Provides Recommendations for Effective PPI Discontinuation

By May 24, 2018

According to the review, a substantial number of patients can effectively decrease or completely discontinue use of PPIs, as often these agents are prescribed without an appropriate reason.

FDA to Review Aemcolo for Treatment of Travelers' Diarrhea

By May 23, 2018

A Phase 3 clinical trial of patients with travelers' diarrhea demonstrated that Aemcolo was superior to placebo (P=.0008) and non-inferior to ciprofloxacin.

Homeopathic Products for Teething, Nausea, Colic, Cough Recalled

By May 18, 2018

Recalled products include Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir.

FDA Approves Hemospray to Treat Non-Variceal GI Bleeds

By May 09, 2018

The product is a single-use device that delivers hemostatic powder through the channel of an endoscope.

Akynzeo for Injection Available for Chemotherapy-Induced Nausea, Vomiting

By May 08, 2018

The intravenous formulation combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.

New Bowel Prep Option for Colonoscopy Gets FDA Approval

By May 07, 2018

The approval of Plenvu was based on multiple clinical trials including the NOCT study which compared Plenvu to the trisulfate bowel cleansing solution Suprep (sodium sulfate, potassium sulfate, magnesium sulfate oral solution; Braintree Laboratories) using a 2-day evening/morning split-dosing regimen.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By May 03, 2018

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

Opioids Often Overprescribed After Hiatal Hernia Surgery

May 03, 2018

Patients use fewer opioids than are prescribed after open, laparoscopic hiatal hernia repair

Wearable Acid Reflux Device Now Available Over-the-Counter

By May 02, 2018

The Reza Band is worn around the neck while sleeping and applies slight external pressure to the cricoid cartilage area, which increases the internal pressure of the upper esophageal sphincter (UES).

FDA Grants Fast Track Status to IBS-D Treatment

By April 26, 2018

ORP-101 is a peripherally active partial agonist of the μ opioid receptor and antagonist of the κ opioid receptor.

Exposure to Anti-TNF Therapy Linked to Reduced Parkinson's Disease Risk

By April 24, 2018

Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.

Factors ID'd to Predict Fatty Liver in Obese Teens

April 24, 2018

"The combination of ethnicity/race with markers of insulin resistance and genetic factors might help identify obese youth at risk for developing fatty liver," the authors write.

IBD and Anemia: Adverse Events After IV Iron Therapy Examined

By April 23, 2018

To examine the occurrence of adverse reactions in this patient population, researchers from John Hopkins University, Baltimore, Maryland, conducted a retrospective analysis of IBD patients who received IV iron infusions between 2010 and 2014 in the commercial claims database, MarketScan.

FDA Approves New Formulation of Akynzeo for CINV

By April 20, 2018

Akynzeo IV combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.

GI Safety Compared for NSAIDs in Patients With Arthritis

By April 19, 2018

The randomized, double-blind, controlled trial (N=24,081) included patients with rheumatoid arthritis or osteoarthritis who required chronic NSAID treatment.

Optimizing organ donations from overdose deaths may help address national organ shortage

April 19, 2018

U.S. transplants using organs from overdose-death donors (ODDs) has increased 24-fold from 2000 to 2016, and transplant outcomes from organs donated by ODDs have been noninferior to those donated by trauma-death donors (TDDs) and medical-death donors (MDDs).

Opiate Use Linked to Early Mortality in IBD Patients

April 18, 2018

Heavy use in Crohn's, heavy or moderate use in ulcerative colitis tied to increased risk of death

<i>C. Difficile</i> Risk Higher With Stoma Reversal vs Difficile

April 18, 2018

Factors associated with C. difficile infection incidence in the 30-day postoperative period after controlling for other variables include stoma reversal (odds ratio, 2.701; P<.001), smoking (odds ratio, 1.520; P<.022), steroids (odds ratio, 1.677; P<.048), and disseminated cancer.

Long-Term Obeticholic Acid Linked to Fibrosis Regression in PBC Patients

By April 13, 2018

Results showed that 46% (n=6) of substudy patients improved their histological fibrosis stage, while 38% maintained (n=5), and 15% experienced 1 stage progression (n=2).